索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]刘佳榛,孙育民,王骏.血液电解质异常与心力衰竭[J].国际心血管病杂志,2021,06:345-348.
点击复制

血液电解质异常与心力衰竭(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年06期
页码:
345-348
栏目:
综述
出版日期:
2021-12-01

文章信息/Info

Title:
-
作者:
刘佳榛; 孙育民; 王骏
200040 上海市静安区中心医院心内科
Author(s):
-
关键词:
心力衰竭;  低钠血症;  低钾血症;  托伐普坦;  低镁血症
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.06.007
文献标识码:
-
摘要:
急慢性心力衰竭(心衰)患者常见的血液电解质异常包括低钠血症、低钾血症、低镁血症等,限制了治疗药物的使用,导致心衰患者的再住院率和死亡率升高。该文介绍心衰合并血液电解质异常的病理机制和治疗策略。
Abstract:
-

参考文献/References

[1] Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure(OPTIME-CHF)study[J]. Circulation, 2005, 111(19):2454-2460.
[2] Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry[J]. Eur Heart J, 2007, 28(8):980-988.
[3] Madan VD, Novak E, Rich MW. Impact of change in serum sodium concentration on mortality in patients hospitalized with heart failure and hyponatremia[J]. Circ Heart Fail, 2011, 4(5):637-643.
[4] Alem MM. Predictors of mortality in patients with chronic heart failure: is hyponatremia a useful clinical biomarker[J]. Int J Gen Med, 2020, 13:407-417.
[5] Su Y, Ma M, Zhang H, et al. Prognostic value of serum hyponatremia for outcomes in patients with heart failure with preserved ejection fraction: An observational cohort study[J]. Exp Ther Med, 2020, 20(5):101.
[6] Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial[J]. JAMA, 2007, 297(12):1319-1331.
[7] Hauptman PJ,Burnett J,Gheorghiade M,et al.Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan[J]. J Card Fail, 2013, 19(6):390-397.
[8] Inomata T, Ikeda Y, Kida K, et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment-results from the K-STAR study[J]. Circ J, 2017, 82(1):159-167.
[9] Udelson JE, Bilsker M, Hauptman PJ, et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction[J]. J Card Fail, 2011, 17(12):973-981.
[10] Jujo K, Saito K, Ishida I, et al. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure[J]. ESC Heart Fail, 2016, 3(3):177-188.
[11] Ng TMH, Grazette LP, Fong MW, et al. Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia(AQUA-AHF)[J]. ESC Heart Fail, 2020, 7(4):1927-1934.
[12] Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial[J]. Eur J Heart Fail, 2007, 9(10):1064-1069.
[13] Oka T, Hamano T, Ohtani T, et al. Renoprotection by long-term low-dose tolvaptan in patients with heart failure and hyponatremia[J]. ESC Heart Fail, Sep 2021.[published online ahead of print]
[14] Covic A, Copur S, Tapoi L, et al. Efficiency of hypertonic saline in the management of decompensated heart failure: a systematic review and meta-analysis of clinical studies[J]. Am J Cardiovasc Drugs, 2021, 21(3):331-347.
[15] Griffin M, Soufer A, Goljo E, et al. Real world use of hypertonic saline in refractory acute decompensated heart failure: A U.S. Center's experience[J]. JACC Heart Fail, 2020, 8(3):199-208.
[16] Ando T, Okuhara Y, Orihara Y, et al. Urinary composition predicts diuretic efficiency of hypertonic saline solution with furosemide therapy and heart failure prognosis[J]. Heart Vessels, 2018, 33(9):1029-1036.
[17] Tuttolomondo A, Maida C, Casuccio A, et al. Effects of intravenous furosemide plus small-volume hypertonic saline solutions on markers of heart failure[J]. ESC Heart Fail, 2021, 8(5):4174-4186.
[18] Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes[J]. Am J Nephrol, 2017, 46(3):213-221
[19] Bowling CB, Pitt B, Ahmed MI, et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies[J]. Circ Heart Fail, 2010, 3(2):253-260.
[20] 中国医师协会心力衰竭专业委员会,国家心血管病专家委员会心力衰竭专业委员会,中华心力衰竭和心肌病杂志编辑委员会. 中国心力衰竭患者离子管理专家共识[J]. 中华心力衰竭和心肌病杂志, 2020, 4(1):16-31.
[21] Ferreira JP, Butler J, Rossignol P, et al. Abnormalities of potassium in heart failure: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020, 75(22):2836-2850.
[22] Valentova M, Patel S, Lam PH, et al. Hypokalaemia and outcomes in older patients hospitalized for heart failure[J].ESC Heart Fail, 2020, 7(3):794-803.
[23] Crespo-Leiro MG, Barge-Caballero E, Segovia-Cubero J, et al. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA heart failure long-term registry[J]. Rev Esp Cardiol(Engl Ed), 2020, 73(4):313-323.
[24] Rakisheva A, Marketou M, Klimenko A, Troyanova-Shchutskaia T, Vardas P. Hyperkalemia in heart failure: Foe or friend[J]. Clin Cardiol, 2020, 43(7):666-675.
[25] Solomon SD, Claggett B, Desai AS, et al. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan(LCZ696)in heart failure with reduced ejection fraction: the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure(PARADIGM-HF)trial[J]. Circ Heart Fail, 2016, 9(3):e002744.
[26] Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate(ZS-9)in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial[J]. Eur J Heart Fail, 2015, 17(10):1050-1056.
[27] Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors[J]. Eur J Heart Fail, 2015, 17(10):1057-1065.
[28] Jiménez-Marrero S, Enjuanes C, Yun S, et al. Use of potassium-binder patiromer for up-titration of renin-angiotensin-aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report[J]. Eur Heart J Case Rep, 2020, 4(4):1-4.
[29] Peacock WF, Rafique Z, Vishnevskiy K, et al. Emergency potassium normalization treatment including sodium zirconium cyclosilicate: a phase Ⅱ, randomized, double-blind, placebo-controlled study(ENERGIZE)[J]. Acad Emerg Med, 2020, 27(6):475-486.
[30] Zannad F, Hsu BG, Maeda Y, et al. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study[J]. ESC Heart Fail, 2020, 7(1):54-64.
[31] Angkananard T, Anothaisintawee T, Eursiriwan S, et al. The association of serum magnesium and mortality outcomes in heart failure patients: A systematic review and meta-analysis[J]. Medicine, 2016, 95(50):e5406.
[32] Nishihara T, Yamamoto E, Sueta D, et al. Clinical significance of serum magnesium levels in patients with heart failure with preserved ejection fraction[J]. Medicine, 2019, 98(38):e17069.
[33] Wannamethee SG, Papacosta O, Lennon L, et al. Serum magnesium and risk of incident heart failure in older men: The British Regional Heart Study[J]. Eur J Epidemiol, 2018, 33(9):873-882.
[34] Liu M, Dudley SC Jr. Magnesium, oxidative stress, inflammation, and cardiovascular Disease[J]. Antioxidants(Basel), 2020, 9(10):907.
[35] Toto RD, Goldenberg R, Chertow GM, et al. Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials[J]. J Diabetes Complications, 2019, 33(10):107402.
[36] Ray EC, Boyd-Shiwarski CR, Liu P, et al. SGLT2 inhibitors for treatment of refractory hypomagnesemia: a case report of 3 patients[J]. Kidney Med, 2020, 2(3):359-364.
[37] Ray EC. Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance[J]. Curr Opin Pharmacol, 2020, 54:11-17.

备注/Memo

备注/Memo:
通信作者:王骏,E-mail:15618612332@163.com
更新日期/Last Update: 2021-12-01